Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate [Seeking Alpha]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Seeking Alpha
Summary Biohaven launches Phase 2/3 study of trigriluzole in Alzheimer's Discussion : Biohaven Pharmaceutical Holding Company ( BHVN ) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expected to begin shortly. Following details of the study plan have been shared by the company. During the 48-week trial period, the 292-subject study will be randomized between trigriluzole and placebo. As a potential modulator of an excitatory neurotransmitter trigriluzole is expected to neuroprotective effects at the synaptic level. The company expects this neuroprotective effect not only to improve synaptic function but also to produce disease-modifying effects in AD. The same drug is also indicated for another Phase 2/3 trial for obsessive compulsive disorder. We have previously covered this CNS-focused company with a strong pipeline including multiple drug candidates in late stage
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock [Yahoo! Finance]Yahoo! Finance
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at HC Wainwright from $50.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $62.00 to $61.00. They now have an "outperform" rating on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at TD Cowen from $35.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/14/23 - Miss
BHVN
Sec Filings
- 3/18/24 - Form DEFA14A
- 3/18/24 - Form DEF
- 3/12/24 - Form 8-K
- BHVN's page on the SEC website